This trial is testing a new, less intense immunosuppressive regimen to see if it can establish engraftment of donor hematopoietic cells while still being safe.
1 Primary · 9 Secondary · Reporting Duration: 2 years post transplant
20 Total Participants · 1 Treatment Group
Primary Treatment: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan · No Placebo Group · Phase 2
Age < 65 · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: